


Cite this: *RSC Adv.*, 2023, 13, 34562

Environmental implications of metal–organic frameworks and MXenes in biomedical applications: a perspective

Bahareh Farasati Far, ^a Navid Rabiee ^{*bc} and Siavash Iravani ^{*d}

Metal–organic frameworks (MOFs) and MXenes have demonstrated immense potential for biomedical applications, offering a plethora of advantages. MXenes, in particular, exhibit robust mechanical strength, hydrophilicity, large surface areas, significant light absorption potential, and tunable surface terminations, among other remarkable characteristics. Meanwhile, MOFs possess high porosity and large surface area, making them ideal for protecting active biomolecules and serving as carriers for drug delivery, hence their extensive study in the field of biomedicine. However, akin to other (nano)materials, concerns regarding their environmental implications persist. The number of studies investigating the toxicity and biocompatibility of MXenes and MOFs is growing, albeit further systematic research is needed to thoroughly understand their biosafety issues and biological effects prior to clinical trials. The synthesis of MXenes often involves the use of strong acids and high temperatures, which, if not properly managed, can have adverse effects on the environment. Efforts should be made to minimize the release of harmful byproducts and ensure proper waste management during the production process. In addition, it is crucial to assess the potential release of MXenes into the environment during their use in biomedical applications. For the biomedical applications of MOFs, several challenges exist. These include high fabrication costs, poor selectivity, low capacity, the quest for stable and water-resistant MOFs, as well as difficulties in recycling/regeneration and maintaining chemical/thermal/mechanical stability. Thus, careful consideration of the biosafety issues associated with their fabrication and utilization is vital. In addition to the synthesis and manufacturing processes, the ultimate utilization and fate of MOFs and MXenes in biomedical applications must be taken into account. While numerous reviews have been published regarding the biomedical applications of MOFs and MXenes, this perspective aims to shed light on the key environmental implications and biosafety issues, urging researchers to conduct further research in this field. Thus, the crucial aspects of the environmental implications and biosafety of MOFs and MXenes in biomedicine are thoroughly discussed, focusing on the main challenges and outlining future directions.

Received 18th October 2023
Accepted 20th November 2023

DOI: 10.1039/d3ra07092a

rsc.li/rsc-advances

1. Introduction

Metal–organic frameworks (MOFs) and MXenes are two classes of materials that have gained considerable attention in recent years due to their exceptional properties and potential applications in various fields of biomedicine.¹ MOFs are porous materials composed of metal ions or clusters coordinated to organic ligands,² while MXenes are two-dimensional (2D) transition metal carbides, nitrides, and carbonitrides.³ MXenes

offer a range of advantages in the field of biomedicine, including high surface area, biodegradability, electrical conductivity, antibacterial properties, tunable surface chemistry, enhanced imaging capabilities, and stimuli-responsive behavior.^{4–6} These characteristics make them promising candidates for various biomedical applications, paving the way for innovative and efficient therapeutic and diagnostic approaches.^{7–9} These materials are highly attractive for a wide range of biomedical applications, including drug delivery,^{10,11} tissue engineering,^{12,13} (bio)sensing,^{8,14–16} and imaging.^{17,18} MOFs can be designed to encapsulate and deliver therapeutic agents, providing controlled release and targeted delivery to specific sites in the body.¹⁹ Meanwhile, MXenes possess excellent electrical conductivity and have been employed in biosensors for sensitive and rapid detection of biomarkers.^{16,20} Notably, both MOFs and MXenes have shown great promises in bioimaging applications, enabling enhanced contrast and precise imaging of biological tissues.²¹

^aDepartment of Chemistry, Iran University of Science and Technology, Tehran, 1684611367, Iran

^bSchool of Engineering, Macquarie University, Sydney, New South Wales, 2109, Australia. E-mail: nrabiee94@gmail.com

^cCentre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Perth, WA, 6150, Australia

^dIndependent Researcher, W Nazar ST, Boostan Ave, Isfahan, Iran. E-mail: siavashira@gmail.com


Numerous promising nanomaterials with potential biomedical uses have emerged in recent years, representing a rapid development in the field of nanomaterials.^{22,23} The special characteristics and wide range of possible uses of MOFs and MXenes have made them the focus of much interest. Because of their high porosity and wide surface area, MOFs are well-suited to serve as carriers for drug delivery and preserving active biomolecules. However, MXenes are expected to rise due to their impressive mechanical strength, hydrophilicity, wide surface areas, strong light absorption potential, and variable surface terminations.²⁴ The structural composition and properties of MOFs and MXenes are still very different, although they are both finding applications in biomedical and environmental application.

The expanding application of MOFs and MXenes in biomedicine requires a comprehensive approach to addressing their environmental effects, which is why they have been chosen as the subject of this perspective.²⁵ Despite their differences, these materials are being investigated for uses such as drug delivery, imaging, biosensing, and tissue engineering, all of which highlight the need of understanding their similarities. This strategy allows us to emphasize the vital significance of identifying the environmental effects of the production, utilization, and disposal of nanomaterials in the biomedical setting, and developing strategies to minimize those impacts.^{26,27}

This viewpoint serves to highlight the unifying issue of environmental responsibility and awareness across these different materials, despite the fact that MOFs and MXenes may differ greatly in their synthesis processes, physicochemical features, and environmental effects. Therefore, our goal in covering both MOFs and MXenes is to give the reader a more

complete picture of the rapidly developing field of nanomaterials in biomedicine and to highlight the importance of environmentally sustainable methods in this field.

While the biomedical applications of MOFs and MXenes hold great promise, it is essential to consider the potential environmental implications associated with their synthesis, utilization, and eventual disposal (Fig. 1). As with any new technology or material, it is crucial to evaluate the environmental impact to ensure sustainable development and minimize any potential risks to human health and the ecosystem. The synthesis and manufacturing processes of MOFs and MXenes involve the use of various chemicals, solvents, and energy-intensive procedures.²⁸ For instance, the synthesis of MOFs often requires the use of organic solvents, which can have adverse effects on human health and the environment.²⁹ These solvents may pose risks of toxicity, flammability, and the release of volatile organic compounds (VOCs) into the atmosphere, contributing to air pollution and potential harm to ecosystems.³⁰ Similarly, the production of MXenes may involve harsh chemical treatments and energy-intensive processes to remove the metallic layers from their parent compounds.³¹ The use of strong acids or etchants in the synthesis of MXenes raises concerns regarding the release of hazardous chemicals and the potential contamination of water sources if proper waste management practices are not implemented.^{32,33} Furthermore, the large-scale production of MOFs and MXenes necessitates the use of significant amounts of resources, including metals and organic ligands. The extraction and processing of these raw materials may have negative environmental impacts, including habitat destruction, water pollution, and energy consumption.^{34–36} It is crucial to assess the sustainability of




Fig. 1 MOFs and MXenes in biomedicine: important aspects and challenges.



these processes and explore alternative methods that minimize the environmental footprint. So far, many reviews have been published regarding the biomedical applications of MOFs and MXenes.^{37–40} Herein, important aspects regarding the environmental implications and biosafety of MOFs and MXenes in biomedicine are deliberated, focusing on main challenges and future directions. In this perspective, it has been tried to express the key issues in environmental implications of them to encourage researchers for more research in this field.

2. Environmental implications in manufacturing of MXenes and MOFs

Various biological applications, from biosensing and drug transport to cancer theranostics and antibacterial treatments, have incorporated MOFs and MXenes because of their exceptional features. However, it is equally important to consider the environmental implications associated with their synthesis, use, and eventual disposal as is their potential for improving healthcare outcomes.

2.1. Synthesis methods and environmental impact

The synthesis process for MOFs and MXenes is a serious environmental problem. Strong acids and high temperature treatments are commonplace in MXene production. These processes can have negative environmental effects and emit toxic byproducts if not well controlled. Researchers must prioritize cleaning up their synthesis processes to protect the environment. There needs to be a system in place to manage waste and reduce the amount of toxic byproducts released during production.⁴¹

Nature serves as a direct source of inspiration for rational design strategies. The structural similarity between natural active components has motivated researchers to explore bio-inspired molecules for applications in biomedical sciences. By leveraging the knowledge of the structural characteristics of these natural components, specific nanomaterial preparation techniques can be employed to create similar active sites within nanostructures, resulting in more effective therapeutic outcomes.⁴² However, recent advancements in understanding MOF synthesis and growth principles have revealed the possibility of effectively incorporating natural active components into MOF backbones through diversification of metal nodes or organic ligands.⁴³ For instance, porphyrin-based MOFs can be modified with functional groups to optimize their optical and electronic properties, as exemplified in the case of MnO₂-coated porphyrin MOFs created to facilitate the oxidation of GSH by MnO₂, resulting in improved PDT, activated magnetic resonance imaging (MRI), and controlled release of doxorubicin for guided MRI drug-PDT dual-therapy.⁴⁴ The incorporation of active components stabilized by MOFs provides an alternative approach to constructing versatile platforms for photodynamic therapy (PDT), sonodynamic therapy (SDT), and catalytic therapy.⁴⁵ For instance, Chen *et al.*⁴⁶ introduced a porous Zr(IV)-based porphyrinic MOF (PZM) nanosystem modified with α -cyano-4-hydroxycinnamate (CHC) to inhibit the expression of

lactate-proton symporter, monocarboxylate transporter 1 (MCT1), thereby reducing lactate uptake in tumor cells. This alteration shifted the energy supply from lactate-fueled aerobic respiration to anaerobic glycolysis, consequently facilitating PDT in cancer treatment by decreasing oxygen consumption in tumor cells. Notably, the PZM nanosystems were coated with hyaluronic acid (HA) for CD44-targeting and hyaluronidase-induced intracellular drug release. Both *in vitro* and *in vivo* studies have demonstrated the favorable biocompatibility and enhanced PDT efficacy of the HA-coated PZM nanosystems in tumor cells.⁴⁶ Researchers have developed a cancer-targeted cascade bioreactor called mCGP by embedding glucose oxidase and catalase in the cancer cell membrane-camouflaged porphyrin MOF known as PCN-224.⁴⁷ The surface functionalization of mCGP mimics biological processes, enhancing its ability to target and remain within cancer cells. Once inside the cancer cells, mCGP promoted oxygenation of the microenvironment by catalyzing the conversion of endogenous H₂O₂ into O₂. This process, combined with light irradiation, could increase the breakdown of intracellular glucose and the production of cytotoxic singlet oxygen (¹O₂). As a result, mCGP exhibited significant synergistic effects in long-term cancer starvation therapy and PDT, effectively inhibiting cancer growth after a single administration. This cascade bioreactor holds promise for the development of complementary approaches to spatiotemporally controlled cancer treatment.⁴⁷ Zhang *et al.*⁴⁸ introduced Cu(II)-nano-MOF that could be easily absorbed by breast cancer cells, leading to the production of high levels of ROS when exposed to light. Simultaneously, the presence of this MOF resulted in a significant reduction in intracellular glutathione levels. This combined effect could synergistically increase ROS concentration and promote apoptosis, thereby enhancing the effectiveness of PDT. Importantly, the prepared MOF exhibited a similar impact to the commercial antitumor drug camptothecin in a mouse model of breast cancer, primarily through the direct adsorption of glutathione.⁴⁸ Furthermore, MOF-derived nitrogen-rich carbon nanostructures, prepared through pyrolysis treatment, offer substrate materials capable of realizing bioinspired design. Abundant nitrogen sites within these structures can anchor metal atoms, forming biomimetic M–N_x sites.⁴⁹ MOF-based nanomaterials inspired by natural components create a suitable microenvironment for the optimal functioning of bio-inspired active components, addressing concerns regarding the low stability and deactivation of natural active components as well as the environmental implications. Moreover, the ordered and periodic arrangement of the porous framework structure in MOFs provides attachment sites for introducing numerous active components, while the well-defined active structure forms the foundation for uncovering chemical reaction mechanisms.^{50–52}

The adoption of circular economy principles in the synthesis of these materials offers a promising avenue for mitigating these environmental challenges. The circular economy approach aims to reduce waste, promote resource efficiency, and minimize environmental harm by prioritizing the reuse, recycling, and recovery of materials.^{53,54} In conventional



synthesis routes, significant amounts of precursors, solvents, and by-products are often wasted, resulting in environmental pollution and resource depletion. By embracing circular economy principles, waste generation can be minimized through various strategies.⁵⁵ One approach is the development of greener and more efficient synthesis processes that optimize the use of raw materials and minimize waste generation. In addition, the recycling and reuse of precursors, solvents, and by-products can further reduce waste and conserve resources.^{56,57} For instance, the utilization of waste streams from other industrial processes as feedstocks for MOF or MXene synthesis can contribute to waste reduction and promote resource circularity.

The circular economy emphasizes the efficient use of resources to minimize the extraction and consumption of virgin materials. In the context of MOFs and MXenes, circular economy principles can be applied to enhance resource efficiency in several ways. Firstly, the selection of sustainable and abundant raw materials for MOF and MXene synthesis reduces reliance on scarce resources. For instance, the use of bio-based or renewable precursors as alternatives to conventional synthetic precursors can contribute to resource efficiency and reduce the environmental footprint. Secondly, the recycling and recovery of MOFs and MXenes at the end of their life cycle can further optimize resource utilization. By implementing effective separation and recovery techniques, valuable components can be extracted from spent MOFs and MXenes, reducing the need for new material production. Circular economy principles play a crucial role in minimizing the environmental impact of MOF and MXene synthesis by promoting the use of less hazardous materials and reducing the release of pollutants.⁵⁸ The substitution of toxic solvents or reagents with safer alternatives can significantly improve the environmental profile of the synthesis processes. In addition, the implementation of closed-loop systems, where waste streams are treated and recycled within the manufacturing process, prevents the discharge of harmful substances into the environment. By minimizing environmental pollution and reducing the overall ecological footprint, the circular economy approach contributes to the sustainable development of MOFs and MXenes. In an impressive study, to assess the cumulative energy demand (CED) and environmental impacts of lab-scale synthesis of MXene ($\text{Ti}_3\text{C}_2\text{T}_x$), a “cradle to gate” life cycle assessment (LCA) was conducted.⁵⁹ The application of electromagnetic interface shielding was selected, and the LCA of MXene synthesis was compared to aluminum and copper foils. The investigation of MXene synthesis focused on various aspects including precursor fabrication, selective etching, delamination processes, laboratory location, energy mix, and raw material type. The findings revealed that more than 70% of the environmental impacts originated from the electricity consumption during the synthesis processes in the laboratory. In comparison, the production of 1.0 kg of industrial-scale aluminum and copper foil emitted 23.0 kg and 8.75 kg of CO_2 , respectively, while the synthesis of 1.0 kg of lab-scale MXene released 428.10 kg of CO_2 . The study indicates that electricity usage has a greater impact than chemical usage, suggesting that incorporating recycled resources and renewable

energy can enhance the sustainability of MXene synthesis. Understanding the LCA of MXenes contributes to the industrialization of this material, enabling informed decisions for its production.⁵⁹

2.2. Biocompatibility and toxicity

Biocompatibility and toxicity are crucial considerations in the context of MOFs and MXenes, as these materials are intended for use within living organisms. Understanding the impact of these nanomaterials on human health and the environment is essential. While MOFs and MXenes hold great promise, there is still ongoing research to thoroughly assess their biocompatibility and potential toxicity. It is imperative to conduct comprehensive studies to determine any potential risks and to develop strategies for safe and sustainable applications.⁶⁰

2.3. Application and disposal considerations

Environmental concerns extend beyond the synthesis process to the application and eventual disposal of MOFs and MXenes in biomedical settings. For instance, the fate of these materials in the human body and their potential release into the environment post-use requires careful examination. Therefore, researchers should consider strategies for ensuring the safe utilization and disposal of these materials to minimize any adverse effects on the environment and public health.⁶¹

3. Environmental implications in biomedical applications of MXenes and MOFs

While the employment of MOFs and MXenes in biomedicine holds great promise, several challenges need to be addressed to ensure their safe and sustainable implementation. In addition, exploring future perspectives in this field can guide researchers toward overcoming these challenges and maximizing the potential benefits of these materials. In this section, we will discuss some of the key challenges and provide insights into the future perspectives of MOFs and MXenes in biomedical applications. From our perspective, some of the important challenges that need to be addressed in this field are (i) biocompatibility and toxicity, (ii) stability, (iii) degradation, (iv) scalability, (v) controlled release and drug loading efficiency, and (vi) manufacturing processes.

The cytotoxicity of MOFs and MXene depends on several factors, including their composition, size, surface properties, and degradation behavior.^{20,62–64} Numerous studies have investigated the cytotoxicity of various MOFs and some of the MXenes using different cell lines and experimental conditions.^{65–68} MOFs have shown relatively low cytotoxicity in many cases.^{19,30,63,69} However, it is important to note that some MOFs have exhibited cytotoxic effects, particularly at higher concentrations or prolonged exposure times. The cytotoxicity mechanisms associated with MOFs can be attributed to several factors.⁷⁰ One factor is the release of metal ions or organic ligands from the MOF structure, which can induce toxicity or



interfere with cellular processes.⁷¹ In addition, the size and surface charge of MOFs can influence their cellular uptake and interactions with intracellular components, potentially leading to cytotoxic effects.⁷² Moreover, the potential presence of impurities or residual reactants from the synthesis process can contribute to the observed cytotoxicity.^{73,74} The cytotoxicity mechanisms of MXenes are still not fully understood and require further investigation. Some studies have suggested that MXenes can induce oxidative stress in cells, leading to cytotoxic effects.⁷⁵ The surface chemistry and functional groups of MXenes can play a role in modulating their cytotoxicity by affecting their interactions with cells and cellular components. In addition, the lateral size and morphology of MXenes can influence their cellular uptake and subsequent intracellular responses.^{60,76} To enhance the biocompatibility of MOFs and MXenes and mitigate potential cytotoxicity and eliminate the potential environmental problems, several strategies can be explored, including (i) using green and sustainable precursors, (ii) surface modifications with natural and biocompatible components like polymers and leaf extracts, (iii) reducing the size of the material, (iv) using natural ligands/linkers on the surface, and (v) using green solvents.

After the employment of MOFs and MXenes for biomedical purposes, these materials may be excreted from the body or disposed of through waste streams. If not properly managed, the release of MOFs and MXenes into the environment could pose potential risks. Their persistence and potential for bioaccumulation raise concerns about their long-term impacts on ecosystems and organisms.^{77–79} To address the environmental implications associated with MOFs and MXenes, researchers and industries must work together to develop sustainable strategies. These strategies include the adoption of green chemistry principles such as using benign solvents, using green and sustainable precursors, reducing energy consumption, and implementing efficient waste management practices. Moreover, the exploration of recycling and reusing MOFs and MXenes can contribute to a circular economy approach, minimizing waste and resource consumption.^{80,81}

3.1. Biosensing

In biosensing, MXene-based materials have emerged as promising candidates because of their unique properties such as high electrical conductivity, large surface area, unique mechanical properties, biocompatibility, and tunable surface properties.^{82–84} MXenes possess a high surface area, which allows for efficient immobilization of biomolecules such as enzymes, antibodies, or DNA probes. This enhanced surface area facilitates a higher loading capacity of biomolecules, leading to improved sensitivity and detection limits in biosensing.^{85,86} In addition, MXenes exhibit excellent electrical conductivity, which enables direct electron transfer between the immobilized biomolecules and the electrode surface, eliminating the need for additional redox mediators. This direct electron transfer enhances the efficiency and speed of the biosensing process, resulting in rapid and real-time detection of target analytes.^{87,88} Notably, MXenes have exceptional

mechanical and chemical stability, making them highly resistant to degradation and providing long-term stability for biosensing applications. This stability ensures the reliability and reproducibility of biosensor performance, even under harsh conditions. MXenes can be also easily functionalized or modified with various functional groups, allowing for the specific recognition and binding of target analytes. This functionalization enhances the selectivity and specificity of biosensors, reducing the chances of false-positive or false-negative results. Lastly, MXenes are compatible with different transduction methods, including optical, electrochemical, and mass-based techniques. This versatility enables the development of diverse biosensing platforms, catering to different analytical needs and applications.^{89–92} MXene-based and MOF-based materials offer desirable properties such as high surface area, tunable pore sizes, and excellent chemical stability, which can enhance the sensitivity and selectivity of biosensors. This, in turn, enables improved detection and analysis of biological molecules, leading to advancements in medical diagnostics and research. While MXenes and MOFs do have unique relevance for their biological applications in biosensing, it is crucial to consider the environmental implications associated with their manufacturing. By addressing these concerns and adopting sustainable practices, researchers can ensure the responsible use of these materials in biomedicine while minimizing their impact on the environment.

The integration of MXene nanosheets with other components can be applied for developing highly sensitive and selective biosensors for the detection of various analytes. These biosensors offer rapid response times, excellent stability, and wide detection ranges, making them suitable for applications in clinical diagnostics and environmental monitoring. In one study, dual-signal electrochemical biosensor was developed for the detection of neutrophil gelatinase-associated lipocalin (NGAL) through the fabrication of MXene-loaded polyaniline nanocomposites as the sensing platform to anchor gold (Au) nanoparticles and immobile primary antibodies.⁹³ Thus, a novel approach was introduced for the early diagnosis of acute kidney injury (AKI) by designing a sensitive dual-signal sandwich-type electrochemical immunosensor for detecting NGAL. After the preparation of an Au NP-loaded copper MOF decorated with a single-walled carbon nanohorn nanocomposite, they bound the NGAL affinity peptide (Pep) to form a Pep/Au/Cu-MOF/SWNH nanocomposite probe. The probe demonstrated two distinct signals for NGAL detection: a square wave voltammetry (SWV) signal and a current–time curve signal; the SWV signal represented electron transfer between Cu^{2+} and Cu^+ of the Cu-MOF, while the current–time curve signal resulted from the reduction of H_2O_2 by the Au/Cu-MOF/SWNH nanocomposite, exhibiting high electrocatalytic activity. The developed immunosensor exhibited excellent analytical performance, with a linear detection range of $0.00001\text{--}10\text{ ng mL}^{-1}$ for NGAL and detection limits of 0.0074 pg mL^{-1} (SWV) and 0.0405 pg mL^{-1} . The researchers further validated the immunosensor by detecting NGAL in a sample, highlighting its potential applications in the diagnosis of acute kidney injury. This study offering a sensitive and reliable method based on MXene and



MOF for early AKI diagnosis, which could ultimately contribute to improved patient outcomes and treatment strategies.⁹³

3.2. Cancer therapy and drug delivery

MXene- and MOF-based nanosystems have been studied for targeted cancer therapy and drug delivery (Fig. 2).^{94,95} The incorporation of therapeutic agents within MXene nanosheets can enable the controlled release and targeted delivery of drugs/therapeutic agents to specific tissues or cells. This approach enhances drug efficacy while minimizing side effects. The evolution of η values is important which represent the loading and release efficiencies of the drugs, providing crucial insights into the performance of MXene-based drug delivery systems. MXene nanosheets have been also explored for photothermal tumor ablation as a promising strategy for cancer therapy. These materials exhibited remarkable photothermal conversion efficiency; they can generate localized hyperthermia upon exposure to near-infrared (NIR) light, resulting in the selective destruction of tumor cells while sparing healthy tissues. In this context, efficient tumor tissue penetration is vital in effective cancer therapy. MXene-based nanosystems can penetrate deep into tumor tissues, ensuring efficient delivery of therapeutic agents and enhancing treatment outcomes. Several optimization processes have been explored to enhance the penetration of MXene nanosheets such as surface modification and size control, providing enhanced tumor targeting and improved therapeutic efficacy.^{96–98}

MOFs can serve as effective drug carriers, providing controlled and targeted delivery of therapeutic agents.^{99,100} They can encapsulate a wide range of drugs, such as chemotherapeutic agents, immunotherapeutic agents, and nucleic acids. They can be employed in PDT, a minimally invasive treatment that utilizes light to activate photosensitizers and generate reactive oxygen species to destroy cancer cells. In this context, MOFs can serve as carriers for photosensitizers, providing protection and controlled release of these agents at the tumor site, enhancing the efficacy of PDT.¹⁰¹ The porous structure of MOFs allows for high drug loading capacity, ensuring efficient delivery to the target site.¹⁰² In addition, MOFs enable the co-delivery of multiple drugs or therapeutic agents. This approach allows for combination therapy, where different drugs with complementary mechanisms of action can be delivered simultaneously.^{103,104} Combination therapy can enhance treatment efficacy, overcome drug resistance, and target multiple pathways involved in cancer progression.¹⁰⁵ MOF-based materials can be engineered to exhibit tunable drug release profiles. By modifying the structure or incorporating stimuli-responsive components, the release of drugs can be controlled based on specific triggers such as changes in pH, temperature, or external stimuli. This controlled release mechanism enhances therapeutic efficacy and reduces side effects.^{106,107} MOFs can be functionalized with targeting ligands or antibodies to selectively bind to cancer cells or specific tissues. This targeted delivery approach improves the specificity of drug delivery, reducing off-

Cancer Therapy & Drug Delivery

Challenges

- ◆ Synthesis Complexity
- ◆ Stability Issues
- ◆ Toxicity Concerns
- ◆ Scalability

Advantages

- ◆ Versatility
- ◆ Enhanced Performance
- ◆ Customizability
- ◆ Controlled Release
- ◆ Combination Therapy
- ◆ Potential for Personalized Medicine
- ◆ Theranostic Applications
- ◆ Synergistic Effects




Fig. 2 Schematic illustration of MXene- and MOF-based materials for targeted cancer therapy and drug delivery, with advantages and important challenges.

target effects and enhancing the accumulation of therapeutic agents at the desired site. Zhao *et al.*¹⁰⁸ developed the lanthanide-doped upconversion nanoparticles (DUCNP)@Mn-MOF nanocarrier, which effectively loaded and delivered a cytotoxic antitumor agent called 3-F-10-OH-evodiamine (FOE). By combining the pH-responsive and peroxidase-like properties of Mn-MOF with the unique optical features of DUCNPs, the prepared system displayed synergistic chemodynamic and chemotherapeutic effects. This nanocarrier successfully addressed the limitations of FOE, including unfavorable physicochemical features and limited *in vivo* potency. It also exhibited excellent tumor targeting capability by responding to the tumor microenvironment. Consequently, this MOF-based nanosystem exhibited selective and bioavailable drug delivery features, holding promise for cancer therapy. In a mouse breast cancer model, DUCNP@Mn-MOF/FOE could effectively inhibit tumor growth without causing noticeable toxicity.¹⁰⁸

While MOF- and MXene-based materials show promising potential in the field of bio- and nanomedicine, it is important

to consider their impact on the environment. Conducting a LCA can provide valuable insights into the environmental impacts of MXenes and MOFs throughout their entire life cycle, including synthesis, usage, and disposal.⁵⁹ This analysis can help identify areas where improvements can be made to reduce their environmental footprint. The toxicity and biocompatibility of MXenes and MOFs need to be thoroughly investigated for their clinical applications in drug delivery and cancer therapy.^{40,109–111} While these materials may offer advantages in drug delivery and therapy, any potential adverse effects on the environment and human health should be carefully evaluated. Long-term studies are necessary to understand their behavior and potential risks.¹⁹ In addition, the synthesis of MOF- and MXene-based systems may involve the use of various chemicals and energy-intensive processes.⁵⁹ These processes can potentially generate waste and emissions, contributing to environmental pollution. It is crucial to develop sustainable and eco-friendly synthesis methods to minimize the environmental impact.^{20,32,112–114}




Fig. 3 The impact of (a) optical characteristics, (b) distribution, and (c) endurance of MXenes on their antimicrobial features. The substantial photothermal conversion efficacy of MXenes could intensify the antibacterial effect through NIR-induced processes, thereby impeding bacterial cells via photothermal therapy. Enhanced dispersion of nanomaterials in water would amplify the available surface area for engaging with bacteria, leading to elevated biocidal rates. Nonetheless, the oxidation of MXene could exert a detrimental influence on this aspect. Reproduced from ref. 125 with permission from Wiley-VCH GmbH, copyright 2023.



3.3. Antibacterial applications

MXene-based composites have demonstrated excellent potential as antibacterial agents, showing great promises in photothermal antibacterial therapy.^{115,116} MXene-based nanosystems are able to disrupt bacterial cell membranes and inhibit bacterial growth. Mechanism studies revealed several antibacterial strategies, including MXene's inherent antibacterial properties with the photothermal effects as well as the release of reactive oxygen species (ROS), leading to synergistic antibacterial effects. These findings pave the way for the development of effective antibacterial systems to combat drug-resistant bacteria.^{115,116} Indeed, the mechanism by which MXene destroys bacterial cell membranes and inhibits bacterial growth is not fully understood. However, it is believed that antimicrobial properties of MXenes are attributed to its ability to disrupt the integrity of bacterial cell membranes. This disruption can lead to leakage of cellular contents, loss of membrane potential, and ultimately cell death. In addition, high surface area and unique physicochemical properties of MXenes may contribute to their antimicrobial activity by promoting interactions with bacterial cells and interfering with essential cellular processes.^{117–120} Further research is needed to fully elucidate the specific mechanisms involved. On the other hand, the antibacterial performance of MOFs is typically associated with physical damage to bacterial cells; MOFs can act as a reservoir of metal ions, which are released to inhibit the growth of bacteria.¹²¹ In this context, there are some strategies to enhance the antibacterial effects of MOF-based systems, which include size modulation, pore size modulation, and adjustment of coordination environment of active sites as well as the design of MOF-based composites by combining MOFs with other materials such as nanoparticles, antibiotics, phytochemicals, and polymers.^{122,123} The surface modification of MOFs can be accomplished by applying photosensitizers with antibacterial purposes; MOF-based systems can also be employed as carriers to transport the agents into the pathogenic bacteria. In addition, the release of antibacterial metal ions or organic ligands from MOF-based systems has shown efficient synergistic antibacterial effects.¹²⁴ Overall, MOFs have great potential for use in antibacterial materials, and it is hoped that their antibacterial qualities will garner more interest in the fields of water and environmental treatment, biomedical science, and materials science, leading to more research and practical applications of MOFs.¹²⁴ Fig. 3 indicates the effects of MXene's optical properties, distribution, and persistence on its antimicrobial attributes. The efficacy of MXenes in photothermal conversion is emphasized, suggesting that they may enhance antibacterial effects *via* NIR-induced mechanisms and impede bacterial cell growth *via* photothermal therapy. In addition, the figure illustrates how enhanced dispersion in water can elevate biocidal rates, though the oxidation of MXene may exert a detrimental influence on this aspect.¹²⁵ Fig. 4 provides a diagrammatic representation of the structural components comprising a Gram-negative bacterial cell (Fig. 4a). Insights into probable scenarios deriving from these interactions are provided by the interaction results between the outer membrane of the bacterial

cell and a bacteriophage, $\text{Ti}_3\text{C}_2\text{T}_x$ MXene, and $\text{Ti}_3\text{C}_2\text{T}_x$ MXene loaded with bacteriophage, as illustrated in Fig. 4b.^{125,126}

4. Challenges and future perspectives

To facilitate the development of effective biosafety materials and solve biosafety-related problems, the integration of biosafety and materials science ought to be considered. Despite great potential of MXenes and MOFs in biomedicine, their implications in the environment should be systematically evaluated.

4.1. MXenes

There is a vital need for further systematic analysis of the biological effects of MXenes, given their great potential for biomedical and environmental applications.¹¹³ MXenes with their unique mechanical properties, large surface area, and substantial light absorption potential have been widely explored for biomedical applications. However, there is still a long way to their clinical uses, which is due to the lack of accurate and pre-clinical tests as well as clinical translation studies and systematic toxicological analyses. Designing next-generation systems with biomedical applications requires comprehensive *in vitro* and *in vivo* assessments, which for MXenes is still in their early stages and requires more elaborate studies.¹²⁷

Biodegradability is one of the crucial factor in biosafety evaluation of MXenes before their biomedical and clinical applications.^{113,127} Since the toxicity and biocompatibility of MXenes are dependent on size, dose, and surface coating, the employment of optimization techniques can help to improve their biosafety.¹²⁸ With employment of surface modification/functionalization strategies such as the adjustment of surface terminations, surface-initiated polymerization, the utilization of small or macromolecules, and single heteroatom techniques, their biosafety as well as their electronic, magnetic, optical, mechanical, and thermal properties can be significantly improved.¹²⁹

4.1.1. Oxidative degradation of MXenes and its implications in biomedicine. Transformation to metal MXenes, especially $\text{Ti}_3\text{C}_2\text{T}_x$, have garnered considerable attention because to their exceptional characteristics and adaptability as nanomaterials—qualitative prospects for a wide range of applications, including biomedicine. Nevertheless, a thorough investigation is justified regarding the fundamental weakness of MXenes, which is their vulnerability to oxidative deterioration upon exposure to air and/or water.¹³⁰ This characteristic has important implication for the characteristics of the materials and biological applications. In this sense, $\text{Ti}_3\text{C}_2\text{T}_x$ MXene functions as a sample example. Its exposure to ambient conditions typically results in rapid oxidative breakdown. As a result of this degradation, its layered, two-dimensional structure decomposes, giving rise to carbon byproducts and titanium dioxide. The degradation in question has substantial consequences, including modifications to the structural and physicochemical characteristics of the material.¹³¹






Fig. 4 (a) Diagram representing the structural components of a Gram-negative bacterial cell. (b) Depiction of three possible outcomes resulting from the interaction between the outer membrane of the bacterial cell and a bacteriophage, Ti₃C₂T_x MXene, and Ti₃C₂T_x MXene loaded with bacteriophage. Reproduced from ref. 125 with permission from Wiley-VCH GmbH, copyright 2023; reproduced from ref. 126 with permission from Elsevier, copyright 2021.



The controlled deterioration of materials such as $\text{Ti}_3\text{C}_2\text{T}_x$ MXene presents promising prospects in particular domains of biomedicine. Significantly, the regulation of therapeutic agent release is an essential stipulation in drug delivery systems. The degradation of MXene, which is initiated by environmental conditions such changes in pH or the presence of particular enzymes, can be applied to accomplish regulated and exact drug release.¹³² Therefore, the utilization of oxidative degradation of MXenes in the development of intelligent drug delivery systems that adapt to certain biochemical or physiological circumstances in a biological system may serve as an advantage. It is important to understand the mechanisms and kinetics by which MXene degrades in various biomedical settings. These insights enable the optimization of material degradation rates to correspond with the temporal demands of various applications, therefore increasing their efficacy.⁴¹

The environmental ramifications and biosafety of MXenes in biomedical applications are significant concerns that are prompted by their oxidative breakdown. Carbon and titanium dioxide, which are byproducts of disintegration, have the ability to enter the environment and exert an impact on ecosystems.¹³³ Furthermore, a thorough evaluation is necessary to determine the toxicity of these results, whether they constitute byproducts of material degradation or are produced after their discharge. It is imperative that stakeholders and researchers assess the prospective advantages and disadvantages linked to the regulated degradation of MXenes in the field of biomedicine, ensuring that their assessment is consistent with wider environmental and biosafety concerns.¹³⁴ By adopting this comprehensive strategy, it provides that the beneficial application of MXenes does not jeopardize the environment, human health, or the intended therapeutic objectives.

4.2. MOFs

MOF-based systems have been designed with unique properties to address major contemporary challenges in the environmental and biomedical fields. Various MOFs have been introduced with drug delivery, imaging, photodynamic therapy, antibacterial, and targeted cancer therapy applications, which can improve fundamental issues in drug development and therapeutic processes. However, it is necessary to analyze the biosafety of MOFs before their clinical applications, as it was indicated in the *in vitro* and *in vivo* toxicity of micron/nanoscale Mg-MOF74. As a result, nanoscale Mg-MOF74 exhibited good biocompatibility with lower cardiotoxicity, demonstrating that the reduction in particle size can be considered as a valuable tactic to improve and expand medical applications of MOFs.^{135,136} Besides, studies revealed that MOFs had a dose-dependent response against cell lines; but, the prepared MOFs have no significant toxicity (*in vitro*).¹³⁷

Beyond the synthesis step, it is important to consider the destiny of MOFs and MXenes when they are applied within biological systems and when they are released into the environment after use. Accordingly, it is crucial to carefully assess methods for safe and environmentally friendly use and disposal

of these materials in biomedical systems. The full environmental impact of these materials, from processing to final disposal, will be considered in the analysis.¹³⁸

Given their proposed use within living organisms, biosafety of MOFs and MXenes in biomedical applications becomes of critical importance. To ensure patient safety and identify any potential downsides, a thorough investigation into their biosafety profile is required. In addition, studies will be conducted *in vitro* and *in vivo* to identify if MOFs and MXenes are biocompatible.¹³⁹ Moreover, a full evaluation of current studies on probable toxicity profiles, comprising known toxicological parameters, will be done. Moreover, case studies or real-world examples can be used to highlight the complexities of environmental issues and suggest possible solutions.

The fascinating properties of MOFs such as high surface area/porosity, adjustable pore sizes, and micro-porous structures can enhance the loading of biomolecules and the encapsulation of different pharmaceuticals/therapeutic agents. But, these features also may raise concerns about the potential toxicity of MOFs.¹⁴⁰ The toxicity of MOFs is mostly due to the degradation and the materials released from them. The toxic effects of MOFs are likely due to the presence of metal ions and functional groups in the organic ligands. In this context, some parameters such as the particle size, functionalized groups, and ligands as well as the solvent system applied for fabricating MOFs and the types of cross-linkers/metals should be considered since they may promote toxicity in MOFs.¹⁴¹ In addition, the selection of solvents for manufacturing MOFs is an important criterion, which can also have toxic effects. Solvents could be confined in the porous MOFs, leading to short- and long-term health effects.¹⁴⁰ It appears that toxicological studies of MOFs are still in their early stages, and more studies are needed to evaluate their environmental implications, particularly the biosafety issues.

5. Conclusion

This review on the environmental implications of MOFs and MXenes in biomedical applications presents several novel insights compared to previous works. It goes beyond the traditional focus on synthesis and applications by emphasizing the environmental fate of MOFs and MXenes, their impact on ecological systems, and the evaluation of their biodegradability and biocompatibility. In addition, the review incorporates life cycle assessments to analyze their overall environmental sustainability and identifies strategies for environmental mitigation. By providing a comprehensive understanding of these materials' environmental implications, the review contributes to advancing sustainable and environmentally friendly applications of MOFs and MXenes in the biomedical field. The employment of MOFs and MXenes in biomedical applications holds tremendous potential for revolutionizing disease treatment, drug delivery, and diagnostics. However, to fully realize their benefits, it is crucial to consider the environmental implications associated with their synthesis and use. This perspective article discussed the role of different green and sustainable approaches in the synthesis of MOFs and MXenes,



highlighting their positive impact on environmental aspects. By embracing the green and sustainable strategies including circular economy principles, waste generation in MOF and MXene synthesis can be significantly reduced. Strategies such as the development of greener synthesis processes, recycling and reuse of precursors and by-products, and the utilization of waste streams contribute to waste reduction and resource circularity. Moreover, these strategies promote resource efficiency by selecting sustainable and abundant raw materials and enabling the recycling and recovery of MOFs and MXenes at the end of their life cycle. Circular economy principles also play a vital role in conserving energy during MOF and MXene synthesis. Optimizing synthesis routes, adopting energy-efficient technologies, and integrating renewable energy sources minimize the environmental impact associated with energy consumption. Furthermore, the use of less hazardous materials and the implementation of closed-loop systems prevent the release of pollutants, thus reducing the overall environmental footprint.

Overall, considering the environmental impact is crucial when evaluating the overall suitability of MXenes and MOFs for biomedical applications.

5.1. Sustainability

The manufacturing processes of MXenes and MOFs can involve the use of various chemicals and energy-intensive procedures. It is important to assess and minimize the environmental footprint of these processes to ensure sustainable production. By adopting greener manufacturing methods, researchers can reduce the carbon footprint and potential ecological damage associated with the production of these materials.

5.2. Toxicity, biocompatibility, and biodegradability

While MXenes and MOFs hold great potential in biomedicine, it is imperative to understand their potential toxicity, biocompatibility, and biodegradability. The environmental implications arise when these materials are released into the environment, either during production or after use. If not properly managed, these materials could potentially accumulate in ecosystems and impact biodiversity. Thus, it is pivotal to study and mitigate any potential adverse effects on the environment.

5.3. Life cycle assessment (LCA)

A comprehensive LCA is essential to evaluate the environmental impact of MXenes and MOFs throughout their entire life cycle, from raw material extraction to manufacturing, use, and disposal. This assessment helps identify areas for improvement and enables the development of more sustainable processes.

Conflicts of interest

The author(s) declare no competing interest.

References

- 1 H. Ding, Y. Li, M. Li, K. Chen, K. Liang, G. Chen, J. Lu, J. Palisaitis, P. O. Å. Persson, P. Eklund, L. Hultman, S. Du, Z. Chai, Y. Gogotsi and Q. Huang, *Science*, 2023, **379**, 1130–1135.
- 2 M. Ding, X. Cai and H.-L. Jiang, *Chem. Sci.*, 2019, **10**, 10209–10230.
- 3 X. Zhan, C. Si, J. Zhou and Z. Sun, *Nanoscale Horiz.*, 2020, **5**, 235–258.
- 4 R. Garg and F. Vitale, *MRS Bull.*, 2023, **48**, 283–290.
- 5 S. M. George and B. Kandasubramanian, *Ceram. Int.*, 2020, **46**, 8522–8535.
- 6 H. Huang, R. Jiang, Y. Feng, H. Ouyang, N. Zhou, X. Zhang and Y. Wei, *Nanoscale*, 2020, **12**, 1325–1338.
- 7 L. Chen, Y. Li, K. Liang, K. Chen, M. Li, S. Du, Z. Chai, M. Naguib and Q. Huang, *Small Methods*, 2023, **7**, 2300054.
- 8 J. Pang, S. Peng, C. Hou, X. Wang, T. Wang, Y. Cao, W. Zhou, D. Sun, K. Wang, M. H. Rummeli, G. Cuniberti and H. Liu, *Nano Res.*, 2022, 1–29, DOI: [10.1007/s12274-022-15272-12278](https://doi.org/10.1007/s12274-022-15272-12278).
- 9 G. Hu, Z. Cen, Y. Xiong and K. Liang, *Nanoscale*, 2023, **15**, 5579–5597.
- 10 S. M. George and B. Kandasubramanian, *Ceram. Int.*, 2020, **46**, 8522–8535.
- 11 J. Cao, X. Li and H. Tian, *Curr. Med. Chem.*, 2020, **27**, 5949–5969.
- 12 M. Shyngys, J. Ren, X. Liang, J. Miao, A. Blocki and S. Beyer, *Front. Bioeng. Biotechnol.*, 2021, **9**, 603608.
- 13 S. Iravani and R. S. Varma, *Mater. Adv.*, 2021, **2**, 2906–2917.
- 14 Y. Lei, W. Zhao, Y. Zhang, Q. Jiang, J. H. He, A. J. Baeumner, O. S. Wolfbeis, Z. L. Wang, K. N. Salama and H. N. Alshareef, *Small*, 2019, **15**, 1901190.
- 15 X.-Q. Wu, Y. Liu, P.-Q. Feng, X.-H. Wei, G.-M. Yang, X.-H. Qiu and J.-G. Ma, *Chem. Commun.*, 2019, **55**, 4059–4062.
- 16 Y. Li, S. Huang, S. Peng, H. Jia, J. Pang, B. Ibarlucea, C. Hou, Y. Cao, W. Zhou, H. Liu and G. Cuniberti, *Small*, 2023, **19**, 2206126.
- 17 H.-S. Wang, *Coord. Chem. Rev.*, 2017, **349**, 139–155.
- 18 M. Huang, Z. Gu, J. Zhang, D. Zhang, H. Zhang, Z. Yang and J. Qu, *J. Mater. Chem. B*, 2021, **9**, 5195–5220.
- 19 S. Mallakpour, E. Nikkhoo and C. M. Hussain, *Coord. Chem. Rev.*, 2022, **451**, 214262.
- 20 G. P. Lim, C. F. Soon, N. L. Ma, M. Morsin, N. Nayan, M. K. Ahmad and K. S. Tee, *Environ. Res.*, 2021, **201**, 111592.
- 21 J. Huang, Z. Li, Y. Mao and Z. Li, *Nano Sel.*, 2021, **2**, 1480–1508.
- 22 V. Eskandari, H. Sahbafar, E. Karooby, M. H. Heris, S. Mehmandoust, D. Razmjoue and A. Hadi, *Spectrochim. Acta, Part A*, 2023, **298**, 122762.
- 23 V. Eskandari, H. Sahbafar, L. Zeinalizad, R. Mahmoudi, F. Karimpour, A. Hadi and H. Bardania, *Arabian J. Chem.*, 2022, **15**, 104005.
- 24 J. Peng, X. Chen, W.-J. Ong, X. Zhao and N. Li, *Chem*, 2019, **5**, 18–50.



- 25 N. H. Solangi, R. R. Karri, N. M. Mubarak and S. A. Mazari, *Adv. Ind. Eng. Polym. Res.*, 2023, DOI: [10.1016/j.aiepr.2023.09.002](#).
- 26 V. Eskandari, A. Hadi and H. Sahbafar, *Adv. Nano Res.*, 2022, **13**, 417–426.
- 27 V. Eskandari, A. Kordzadeh, L. Zeinalizad, H. Sahbafar, H. Aghanouri, A. Hadi and S. Ghaderi, *Opt. Mater.*, 2022, **128**, 112310.
- 28 X. Zhuang, S. Zhang, Y. Tang, F. Yu, Z. Li and H. Pang, *Coord. Chem. Rev.*, 2023, **490**, 215208.
- 29 N. Stock and S. Biswas, *Chem. Rev.*, 2012, **112**, 933–969.
- 30 S. Kumaraguru, R. Nivetha, K. Gopinath, E. Sundaravadivel, B. O. Almutairi, M. H. Almutairi, S. Mahboob, M. Kavipriya, M. Nicoletti and M. Govindarajan, *J. Mater. Res. Technol.*, 2022, **18**, 1732–1745.
- 31 J. A. Kumar, P. Prakash, T. Krithiga, D. J. Amarnath, J. Premkumar, N. Rajamohan, Y. Vasseghian, P. Saravanan and M. Rajasimman, *Chemosphere*, 2022, **286**, 131607.
- 32 A. Rozmysłowska-Wojciechowska, A. Szuplewska, T. Wojciechowski, S. Poźniak, J. Mitrzak, M. Chudy, W. Ziemkowska, L. Chlubny, A. Olszyna and A. M. Jastrzębska, *Mater. Sci. Eng. C*, 2020, **111**, 110790.
- 33 A. Jastrzębska, A. Szuplewska, T. Wojciechowski, M. Chudy, W. Ziemkowska, L. Chlubny, A. Rozmysłowska and A. Olszyna, *J. Hazard. Mater.*, 2017, **339**, 1–8.
- 34 M. Naguib, M. W. Barsoum and Y. Gogotsi, *Adv. Mater.*, 2021, **33**, 2103393.
- 35 J. J. Y. Lim and A. N. K. Lup, *Environ. Sci.: Adv.*, 2022, **1**, 570–583.
- 36 S. Liu, Z. Teng, H. Liu, T. Wang, G. Wang, Q. Xu, X. Zhang, M. Jiang, C. Wang and W. Huang, *Angew. Chem.*, 2022, **134**, e202207026.
- 37 N. H. Solangi, S. A. Mazari, N. M. Mubarak, R. R. Karri, N. Rajamohan and D.-V. N. Vo, *Environ. Res.*, 2023, **222**, 115337.
- 38 S. S. Siwal, H. Kaur, G. Chauhan and V. K. Thakur, *Adv. NanoBiomed Res.*, 2023, **3**, 2200123.
- 39 L. He, M. Shang, Z. Chen and Z. Yang, *Chem. Rec.*, 2023, e202300018, DOI: [10.1002/tcr.202300018](#).
- 40 M. Moharramnejad, A. Ehsani, M. Shahi, S. Gharanli, H. Saremi, R. E. Malekshah, Z. S. Basmenj, S. Salmani and M. Mohammadi, *J. Drug Delivery Sci. Technol.*, 2023, **81**, 104285.
- 41 A. Khosla, Sonu, H. T. A. Awan, K. Singh, Gaurav, R. Walvekar, Z. Zhao, A. Kaushik, M. Khalid and V. Chaudhary, *Adv. Sci.*, 2022, **9**, 2203527.
- 42 S. Zhang, M. Zheng, Y. Tang, R. Zang, X. Zhang, X. Huang, Y. Chen, Y. Yamauchi, S. Kaskel and H. Pang, *Adv. Funct. Mater.*, 2022, **32**, 2204714.
- 43 S. Kitagawa, *Chem. Soc. Rev.*, 2014, **43**, 5415–5418.
- 44 X.-T. Tian, P.-P. Cao, H. Zhang, Y.-H. Li and X.-B. Yin, *Chem. Commun.*, 2019, **55**, 6241–6244.
- 45 W. Yu, W. Zhen, Q. Zhang, Y. Li, H. Luo, J. He and Y. Liu, *ChemMedChem*, 2020, **15**, 1766–1775.
- 46 Z.-X. Chen, M.-D. Liu, M.-K. Zhang, S.-B. Wang, L. Xu, C.-X. Li, F. Gao, B.-R. Xie, Z.-L. Zhong and X.-Z. Zhang, *Adv. Funct. Mater.*, 2018, **28**, 1803498.
- 47 S.-Y. Li, H. Cheng, B.-R. Xie, W.-X. Qiu, J.-Y. Zeng, C.-X. Li, S.-S. Wan, L. Zhang, W.-L. Liu and X.-Z. Zhang, *ACS Nano*, 2017, **11**, 7006–7018.
- 48 W. Zhang, J. Lu, X. Gao, P. Li, W. Zhang, Y. Ma, H. Wang and B. Tang, *Angew. Chem.*, 2018, **57**, 4891–4896.
- 49 X. Han, W.-M. Chen, X. Han, Y.-Z. Tan and D. Sun, *J. Mater. Chem. A*, 2016, **4**, 13040–13045.
- 50 B. Xu, Z. Huang, Y. Liu, S. Li and H. Liu, *Nano Today*, 2023, **48**, 101690.
- 51 S. F. Fatima, R. Sabouni, R. Garg and H. Gomaa, *Colloids Surf., B*, 2023, 113266.
- 52 J. Tang, C. Huang, Y. Liu, T. Wang, M. Yu, H. Hao, W. Zeng, W. Huang, J. Wang and M. Wu, *Coord. Chem. Rev.*, 2023, **490**, 215211.
- 53 H. Corvellec, A. F. Stowell and N. Johansson, *J. Ind. Ecol.*, 2022, **26**, 421–432.
- 54 M. Geissdoerfer, P. Savaget, N. M. Bocken and E. J. Hultink, *J. Cleaner Prod.*, 2017, **143**, 757–768.
- 55 W. R. Stahel, *Nature*, 2016, **531**, 435–438.
- 56 J. Korhonen, A. Honkasalo and J. Seppälä, *Ecol. Econ.*, 2018, **143**, 37–46.
- 57 R. Cucciniello and D. Cespi, *Recycling*, 2018, **3**, 22.
- 58 A. S. Jatoti, N. M. Mubarak, Z. Hashmi, N. H. Solangi, R. R. Karri, T. Y. Hua, S. A. Mazari, J. R. Koduru and A. Alfantazi, *Chemosphere*, 2022, 137497.
- 59 M. D. Firouzjaei, S. K. Nemani, M. Sadrzadeh, E. K. Wujcik, M. Elliott and B. Anasori, *Adv. Mater.*, 2023, **35**, 2300422.
- 60 H. Huang, R. Jiang, Y. Feng, H. Ouyang, N. Zhou, X. Zhang and Y. Wei, *Nanoscale*, 2020, **12**, 1325–1338.
- 61 J. Chen, Q. Huang, H. Huang, L. Mao, M. Liu, X. Zhang and Y. Wei, *Nanoscale*, 2020, **12**, 3574–3592.
- 62 C. Tamames-Tabar, D. Cunha, E. Imbuluzqueta, F. Ragon, C. Serre, M. J. Blanco-Prieto and P. Horcajada, *J. Mater. Chem. B*, 2014, **2**, 262–271.
- 63 Q. Hu, J. Yu, M. Liu, A. Liu, Z. Dou and Y. Yang, *J. Med. Chem.*, 2014, **57**, 5679–5685.
- 64 J. Wu, Y. Yu and G. Su, *Nanomaterials*, 2022, **12**, 828.
- 65 W. Shang, L. Peng, P. Guo, H. Hui, X. Yang and J. Tian, *ACS Biomater. Sci. Eng.*, 2019, **6**, 1008–1016.
- 66 A. M. Jastrzębska, B. Scheibe, A. Szuplewska, A. Rozmysłowska-Wojciechowska, M. Chudy, C. Aparicio, M. Scheibe, I. Janica, A. Ciesielski and M. Otyepka, *Mater. Sci. Eng. C*, 2021, **119**, 111431.
- 67 S. Ahmadi, V. Jajarmi, M. Ashrafzadeh, A. Zarrabi, J. T. Haponiuk, M. R. Saeb, E. C. Lima, M. Rabiee and N. Rabiee, *J. Hazard. Mater.*, 2022, **436**, 129259.
- 68 N. Rabiee, M. Bagherzadeh, M. Jouyandeh, P. Zarrintaj, M. R. Saeb, M. Mozafari, M. Shokouhimehr and R. S. Varma, *ACS Appl. Bio Mater.*, 2021, **4**, 5106–5121.
- 69 Z.-C. Wang, Y. Zhang and Z.-Y. Li, *J. Cluster Sci.*, 2018, **29**, 1285–1290.
- 70 F. Hao, Z. Y. Yan and X. P. Yan, *Small Sci.*, 2022, **2**, 2200044.



- 71 M. Ahmadi, S. M. Ayyoubzadeh, F. Ghorbani-Bidkorbeh, S. Shahhosseini, S. Dadashzadeh, E. Asadian, M. Mosayebnia and S. Siavashy, *Heliyon*, 2021, **7**, e06914.
- 72 L. Treuel, X. Jiang and G. U. Nienhaus, *J. R. Soc., Interface*, 2013, **10**, 20120939.
- 73 A. Ma, Z. Luo, C. Gu, B. Li and J. Liu, *Inorg. Chem. Commun.*, 2017, **77**, 68–71.
- 74 M. Ibrahim, W. H. Abuwatfa, N. S. Awad, R. Sabouni and G. A. Hussein, *Pharmaceutics*, 2022, **14**, 254.
- 75 B. e. Scheibe, J. K. Wychowanec, M. Scheibe, B. Peplinska, M. Jarek, G. Nowaczyk and Ł. Przysiecka, *ACS Biomater. Sci. Eng.*, 2019, **5**, 6557–6569.
- 76 V. S. Sivasankarapillai, A. K. Somakumar, J. Joseph, S. Nikazar, A. Rahdar and G. Z. Kyzas, *Nano-Struct. Nano-Objects*, 2020, **22**, 100457.
- 77 S. Iravani and R. S. Varma, *Nanomaterials*, 2022, **12**, 1200.
- 78 A. Jastrzębska, A. Szuplewska, A. Rozmysłowska-Wojciechowska, M. Chudy, A. Olszyna, M. Birowska, M. Popielski, J. Majewski, B. Scheibe and V. Natu, *2D Materials*, 2020, **7**, 025018.
- 79 B. Rashid, A. Anwar, S. Shahabuddin, G. Mohan, R. Saidur, N. Aslfattahi and N. Sridewi, *Materials*, 2021, **14**, 4370.
- 80 V. V. Butova, I. A. Pankin, O. A. Burachevskaya, K. S. Vetlitsyna-Novikova and A. V. Soldatov, *Inorg. Chim. Acta*, 2021, **514**, 120025.
- 81 H. Shi, M. Yue, C. J. Zhang, Y. Dong, P. Lu, S. Zheng, H. Huang, J. Chen, P. Wen and Z. Xu, *ACS Nano*, 2020, **14**, 8678–8688.
- 82 R. Khan and S. Andreescu, *Sensors*, 2020, **20**, 5434.
- 83 B. Xu, C. Zhi and P. Shi, *J. Phys.: Mater.*, 2020, **3**, 031001.
- 84 Z. U. D. Babar, B. D. Ventura, R. Velotta and V. Iannotti, *RSC Adv.*, 2022, **12**, 19590–19610.
- 85 S. Alwarappan, N. Nesakumar, D. Sun, T. Y. Hu and C.-Z. Li, *Biosens. Bioelectron.*, 2022, **205**, 113943.
- 86 Z. Wang, Z. Zhang, Y. Zhang, X. Xu, T. Shen, H. Pan and D. Chang, *Talanta*, 2023, **265**, 124848.
- 87 S. K. Bhardwaj, H. Singh, M. Khatri, K.-H. Kim and N. Bhardwaj, *Biosens. Bioelectron.*, 2022, **202**, 113995.
- 88 K. Deshmukh, T. Kovářik and S. K. Pasha, *Coord. Chem. Rev.*, 2020, **424**, 213514.
- 89 S. Kumar, Y. Lei, N. H. Alshareef, M. A. Quevedo-Lopez and K. N. Salama, *Biosens. Bioelectron.*, 2018, **121**, 243–249.
- 90 L. Lorencova, V. Gajdosova, S. Hroncekova, T. Bertok, J. Blahutova, A. Vikartovska, L. Parrakova, P. Gemeiner, P. Kasak and J. Tkac, *Electroanalysis*, 2019, **31**, 1833–1844.
- 91 D. Lu, H. Zhao, X. Zhang, Y. Chen and L. Feng, *Biosensors*, 2022, **12**, 820.
- 92 X. Zhu, Y. Zhang, M. Liu and Y. Liu, *Biosens. Bioelectron.*, 2021, **171**, 112730.
- 93 H. Liang, C. Chen, J. Zeng, M. Zhou, L. Wang, G. Ning, Q. Duan, R. Han, H. Liu and H. Zhao, *ACS Appl. Nano Mater.*, 2022, **5**, 16774–16783.
- 94 L. M. Dong, C. Ye, L. L. Zheng, Z. F. Gao and F. Xia, *Nanophotonics*, 2020, **9**, 2125–2145.
- 95 S. Iravani and R. S. Varma, *ACS Biomater. Sci. Eng.*, 2021, **7**, 1900–1913.
- 96 X. Han, X. Jing, D. Yang, H. Lin, Z. Wang, H. Ran, P. Li and Y. Chen, *Theranostics*, 2018, **8**, 4491–4508.
- 97 C. Xing, S. Chen, X. Liang, Q. Liu, M. Qu, Q. Zou, J. Li, H. Tan, L. Liu, D. Fan and H. Zhang, *ACS Appl. Mater. Interfaces*, 2018, **10**, 27631–27643.
- 98 B. Zhou, H. Yin, C. Dong, L. Sun, W. Feng, Y. Pu, X. Han, X. Li, D. Du, H. Xu and Y. Chen, *Advanced Science*, 2021, **8**, 2101043.
- 99 Y. Ye, Y. Zhao, Y. Sun and J. Cao, *Int. J. Nanomed.*, 2022, **17**, 2367–2395.
- 100 S. F. Fatima, R. Sabouni, R. Garg and H. Gomaa, *Colloids Surf., B*, 2023, **225**, 113266.
- 101 G. G. Matlou and H. Abrahamse, *Front. Chem.*, 2022, **10**, 971747.
- 102 H. D. Lawson, S. P. Walton and C. Chan, *ACS Appl. Mater. Interfaces*, 2021, **13**, 7004–7020.
- 103 J.-Q. Liu, Z. Lin, D. Liao, C. Jiang, H. Song, A. Nezamzadeh-Ejhi, M. Zheng, H. Yuan and C. Lu, *RSC Med. Chem.*, 2023, **14**, 1914–1933.
- 104 M. B. Alahri, R. Arshadizadeh, M. Raeisi, M. Khatami, M. S. Sajadi, W. K. Abdelbasset, R. Akhmadeev and S. Iravani, *Inorg. Chem. Commun.*, 2021, **134**, 108997.
- 105 R. B. Mokhtari, T. S. Homayouni, N. Baluch, E. Morgatskaya, S. Kumar, B. Das and H. Yeger, *Oncotarget*, 2017, **8**, 38022–38043.
- 106 Y. Zhang, X. Wang, R. Wang, Y. Chen, L. Wang, Y. Shi, Z. Wang, W. Niu and W. Shi, *New J. Chem.*, 2023, **47**, 15407–15421.
- 107 J. Yang, D. Dai, X. Zhang, L. Teng, L. Ma and Y.-W. Yang, *Theranostics*, 2023, **13**, 295–323.
- 108 X. Zhao, S. He, B. Li, B. Liu, Y. Shi, W. Cong, F. Gao, J. Li, F. Wang, K. Liu, C. Sheng, J. Su and H.-G. Hu, *Nano Lett.*, 2023, **23**, 863–871.
- 109 F. Mohajer, G. Mohammadi Ziarani, A. Badiei, S. Iravani and R. S. Varma, *Micromachines*, 2022, **13**, 1773.
- 110 M. R. Saeb, N. Rabiee, M. Mozafari, F. Verpoort, L. G. Voskressensky and R. Luque, *Materials*, 2021, **14**, 7277.
- 111 M.-X. Wu and Y.-W. Yang, *Adv. Mater.*, 2017, **29**, 1606134.
- 112 A. M. Jastrzębska, A. Szuplewska, T. Wojciechowski, M. Chudy, W. Ziemkowska, L. Chlubny, A. Rozmysłowska and A. Olszyna, *J. Hazard. Mater.*, 2017, **339**, 1–8.
- 113 I. A. Vasyukova, O. V. Zakharova, D. V. Kuznetsov and A. A. Gusev, *Nanomaterials*, 2022, **12**, 1797.
- 114 A. Mandal, S. Ganguly, S. Mukherjee and D. Das, *Dalton Trans.*, 2019, **48**, 13869–13879.
- 115 M. Khatami, P. Iravani, G. Jamalipour Soufi and S. Iravani, *Mater. Technol.*, 2022, **37**, 1890–1905.
- 116 S. Iravani and R. S. Varma, *RSC Adv.*, 2023, **13**, 9665–9677.
- 117 C. Guo, F. Cheng, G. Liang, S. Zhang, S. Duan, Y. Fu, F. Marchetti, Z. Zhang and M. Du, *Adv. NanoBiomed Res.*, 2022, **2**, 2200064.
- 118 K. Rasool, M. Helal, A. Ali, C. E. Ren, Y. Gogotsi and K. A. Mahmoud, *ACS Nano*, 2016, **10**, 3674–3684.
- 119 S. S. Sana, M. Santhamoorthy, R. Haldar, C. J. Raorane, S. Iravani, R. S. Varma and S.-C. Kim, *Process Biochem.*, 2023, **132**, 200–220.



- 120 F. Seidi, A. A. Shamsabadi, M. D. Firouzjaei, M. Elliott, M. R. Saeb, Y. Huang, C. Li, H. Xiao and B. Anasori, *Small*, 2023, 2206716, DOI: [10.1002/sml.202206716](https://doi.org/10.1002/sml.202206716).
- 121 N. Bhardwaj, S. K. Pandey, J. Mehta, S. K. Bhardwaj, K.-H. Kim and A. Deep, *Toxicol. Res.*, 2018, 7, 931–941.
- 122 X. Zhang, F. Peng and D. Wang, *J. Funct. Biomater.*, 2022, **13**, 215.
- 123 M. Shen, F. Forghani, X. Kong, D. Liu, X. Ye, S. Chen and T. Ding, *Compr. Rev. Food Sci. Food Saf.*, 2020, **19**, 1397–1419.
- 124 Y. Li, X. Xia, W. Hou, H. Lv, J. Liu and X. Li, *Int. J. Nanomed.*, 2023, **18**, 1109–1128.
- 125 F. Seidi, A. Arabi Shamsabadi, M. Dadashi Firouzjaei, M. Elliott, M. R. Saeb, Y. Huang, C. Li, H. Xiao and B. Anasori, *Small*, 2023, **19**, 2206716.
- 126 M. Mansoorianfar, K. Shahin, A. Hojjati-Najafabadi and R. Pei, *Chemosphere*, 2022, **290**, 133383.
- 127 L. Chen, X. Dai, W. Feng and Y. Chen, *Acc. Mater. Res.*, 2022, **3**, 785–798.
- 128 H. Li, R. Fan, B. Zou, J. Yan, Q. Shi and G. Guo, *J. Nanobiotechnol.*, 2023, **21**, 73, DOI: [10.1186/s12951-12023-01809-12952](https://doi.org/10.1186/s12951-12023-01809-12952).
- 129 M. Mozafari and M. Soroush, *Adv. Mater.*, 2021, **2**, 7277–7307.
- 130 A. Iqbal, J. Hong, T. Y. Ko and C. M. Koo, *Nano Convergence*, 2021, **8**, 1–22.
- 131 M. S. Javed, A. Mateen, I. Hussain, A. Ahmad, M. Mubashir, S. Khan, M. A. Assiri, S. M. Eldin, S. S. A. Shah and W. Han, *Energy Storage Mater.*, 2022, **53**, 827–872.
- 132 Y. Wang, Z. Li and Q. Hu, *Nano Today*, 2021, **38**, 101127.
- 133 P. G. Moradeeya, A. Sharma, M. A. Kumar and S. Basha, *Environ. Res.*, 2022, **204**, 112384.
- 134 H. Lin, Y. Chen and J. Shi, *Advanced Science*, 2018, **5**, 1800518.
- 135 Z. Zhu, S. Jiang, Y. Liu, X. Gao, S. Hu, X. Zhang, C. Huang, Q. Wan, J. Wang and X. Pei, *Nano Res.*, 2020, **13**, 511–526.
- 136 S. Cao, Y. Li, Y. Tang, Y. Sun, W. Li, X. Guo, F. Yang, G. Zhang, H. Zhou and Z. Liu, *Adv. Mater.*, 2023, 2301011.
- 137 M. Salehipour, S. Nikpour, S. Rezaei, S. Mohammadi, M. Rezaei, D. Ilbeygi, A. Hosseini-Chegeni and M. Mogharabi-Manzari, *Inorg. Chem. Commun.*, 2023, **152**, 110655.
- 138 S. Saxena, M. Johnson, F. Dixit, K. Zimmermann, S. Chaudhuri, F. Kaka and B. Kandasubramanian, *Renewable Sustainable Energy Rev.*, 2023, **178**, 113238.
- 139 S. Sagadevan and W.-C. Oh, *J. Drug Delivery Sci. Technol.*, 2023, 104569.
- 140 M. Al Sharabati, R. Sabouni and G. A. Hussein, *Nanomaterials*, 2022, **12**, 277.
- 141 P. Kumar, B. Anand, Y. F. Tsang, K.-H. Kim, S. Khullar and B. Wang, *Environ. Res.*, 2019, **176**, 108488.

